Press release
Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market to Reach US$ 30.85 Billion by 2033 at 18.6% CAGR; North America Dominates with 54.80% Share - Key Players: Genfit, Novo Nordisk, Gilead Sciences
The global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market was valued at USD 8.95 billion in 2025 and is projected to reach USD 30.85 billion by 2033, registering a CAGR of 18.6% during the forecast period 2026-2033. This represents an absolute market value increase of USD 21.90 billion, equivalent to approximately 244.7% growth over the forecast period, highlighting the expanding commercial potential of liver disease treatment and diagnostic solutions.Market growth is driven by the rising prevalence of metabolic dysfunction-associated steatohepatitis (MASH), increasing rates of obesity and type 2 diabetes, and growing awareness of liver-related complications. Advancements in non-invasive diagnostic technologies, biomarker-based testing, and imaging solutions are improving early disease detection and monitoring. At the same time, expanding clinical pipelines, the development of targeted therapeutics, and increasing investment in innovative treatment approaches are creating significant opportunities for pharmaceutical, biotechnology, and diagnostic companies.
Get a Free Sample PDF of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/non-alcoholic-steatohepatitis-therapeutics-and-diagnostics-market?sai-v
Recent Developments
September 9, 2026: GENFIT highlighted the commercial potential of its NIS4 and next-generation NIS2+ blood-based diagnostic technologies for identifying patients with at-risk MASH.
September 2, 2026: Researchers published a review in Nature examining emerging MASH therapies, including FGF21 analogues, PPAR agonists, and incretin-based treatments.
August 2026: GENFIT expanded the commercial development of its NASHnext diagnostic technology through growing reimbursement coverage and clinical adoption of non-invasive blood testing.
April 10, 2026: Researchers reviewed ongoing MASH clinical trials, highlighting developments in resmetirom, semaglutide, and emerging therapies targeting liver inflammation and fibrosis.
Key Players
Allergan plc. | Pfizer Inc. | Gilead Sciences, Inc. | Genfit SA | Novartis AG | Intercept Pharmaceuticals, Inc. | Cadila Healthcare Ltd. | Novo Nordisk A/S | Raptor Pharmaceutical Corp. | Galmed Pharmaceuticals Ltd. | Others
Buy Now to Acess Full Report: https://www.datamintelligence.com/buy-now-page?report=non-alcoholic-steatohepatitis-therapeutics-and-diagnostics-market?sai-v
Market Drivers
Rising Prevalence of Metabolic Disorders: Increasing cases of obesity, type 2 diabetes, insulin resistance and metabolic syndrome are expanding the patient population requiring NASH diagnosis and treatment.
Growing Demand for Advanced Therapeutics: Increasing demand for disease-specific treatments is supporting the adoption of emerging therapies, including resmetirom and investigational metabolic treatments.
Increasing Awareness of Liver Diseases: Greater awareness of NASH and its progression to liver fibrosis and cirrhosis is encouraging early diagnosis, disease monitoring and timely treatment.
Advancements in Diagnostic Technologies: Growing adoption of non-invasive diagnostic methods, including elastography, imaging techniques and blood-based biomarkers, is improving disease detection and assessment.
Expansion of Clinical Research: Rising pharmaceutical investments in clinical trials targeting liver inflammation, metabolic dysfunction and fibrosis are supporting the development of new therapeutic options.
Industry Developments
Disease-Specific Drug Commercialization: The introduction of approved NASH/MASH therapies is creating new treatment opportunities and encouraging pharmaceutical companies to expand their commercialization strategies.
Clinical Pipeline Expansion: Drug developers are advancing investigational therapies targeting different disease pathways, including GLP-1, THR-beta and FGF21 mechanisms.
Non-Invasive Diagnostic Innovation: Companies are developing advanced imaging solutions and biomarker-based tests to reduce dependence on invasive liver biopsies.
Combination Therapy Research: Pharmaceutical researchers are investigating combination treatment approaches to address metabolic dysfunction, liver inflammation and fibrosis progression.
AI-Based Diagnostic Integration: Healthcare technology providers are exploring artificial intelligence and advanced analytics to improve liver imaging interpretation and disease assessment.
Strategic Pharmaceutical Collaborations: Drug manufacturers, diagnostic companies and research institutions are strengthening partnerships to accelerate clinical development, diagnostic innovation and treatment access.
Regional Insights
North America: Dominates the global market, accounting for 54.80% market share, supported by advanced healthcare infrastructure, strong pharmaceutical research activity, established diagnostic networks and early adoption of innovative NASH therapies.
Europe: Holds 22.17% market share, driven by established hepatology services, increasing awareness of metabolic liver diseases and growing adoption of advanced diagnostic technologies.
Asia-Pacific: Accounts for 18.09% market share and represents the fastest-growing regional market, supported by rising obesity and diabetes prevalence, expanding healthcare infrastructure and increasing demand for liver disease diagnosis and treatment.
Latin America: Represents 2.96% market share, with growth supported by improving diagnostic accessibility, increasing metabolic disease prevalence and gradual expansion of specialist healthcare services.
Middle East & Africa: Accounts for 1.99% market share, supported by rising metabolic disorders, healthcare infrastructure development and growing awareness of advanced liver disease management.
Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/non-alcoholic-steatohepatitis-therapeutics-and-diagnostics-market?sai-v
Key Segments
➥ By Therapeutics
Ocaliva: Includes obeticholic acid, a farnesoid X receptor (FXR) agonist investigated for its potential role in managing NASH and liver fibrosis.
Elafibranor: Covers a dual PPAR-alpha/delta agonist developed to target metabolic dysfunction, inflammation, and liver-related conditions associated with NASH.
Cenicriviroc: Includes an investigational CCR2/CCR5 antagonist designed to target inflammatory and fibrotic pathways associated with NASH progression.
Selonsertib: Covers an investigational ASK1 inhibitor studied for its potential to reduce liver inflammation and fibrosis.
Others: Includes additional therapeutic candidates and pharmacological treatments developed to manage NASH, liver inflammation, and fibrosis.
➥ By Diagnostics
Imaging Techniques: Includes ultrasound, magnetic resonance imaging, transient elastography, and other non-invasive imaging methods used to assess liver fat and fibrosis.
Diagnostic Tests: Covers blood-based tests, liver function tests, biomarker assessments, and non-invasive scoring systems used to evaluate NASH progression.
Biopsy: Includes liver biopsy procedures used to examine liver tissue and assess inflammation, steatosis, and fibrosis severity.
➥ By Sales Channel
Hospital Pharmacy: Includes NASH therapeutics and diagnostic products distributed through hospital pharmacies for inpatient and outpatient care.
Online Channel: Covers medicines and diagnostic-related products supplied through authorized online pharmacy platforms and digital healthcare channels.
Retail Channel: Includes products distributed through independent pharmacies, pharmacy chains, and other physical retail outlets.
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market to Reach US$ 30.85 Billion by 2033 at 18.6% CAGR; North America Dominates with 54.80% Share - Key Players: Genfit, Novo Nordisk, Gilead Sciences here
News-ID: 4690647 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Microfluidic Coolants Market to Reach US$3,442.71 Million by 2035 | Microfluidic …
The semiconductor industry's transition toward increasingly powerful processors is changing how manufacturers approach thermal management. AI accelerators, graphics processing units (GPUs), high-bandwidth memory (HBM) and three-dimensional integrated circuits (3D ICs) generate concentrated heat that conventional cooling architectures may struggle to dissipate efficiently. Microfluidic cooling addresses this challenge by circulating fluids through microscopic channels positioned close to heat-generating components.
This shift is also changing the commercial importance of coolant formulations. Viscosity,…
NASH/MASH Treatment Market to Reach US$ 33.02 Billion by 2035 at 17.55% CAGR; Ri …
The global NASH/MASH treatment market was valued at US$ 8.13 billion in 2025 and is projected to reach US$ 33.02 billion by 2035, registering a CAGR of 17.55% during the forecast period 2026-2035. This represents an absolute market value increase of US$ 24.89 billion, equivalent to approximately 306.2% growth over the forecast period, highlighting the rapidly expanding potential of treatments for metabolic liver diseases.
Market growth is driven by the rising…
Electronic Chemicals and Materials Market to Reach US$102.16 Billion by 2033 | E …
The electronic chemicals and materials market is entering a strategically important phase as semiconductor manufacturers increase investments in advanced fabrication, high-performance computing and next-generation packaging. The transition toward smaller process nodes, complex chip architectures and higher-density interconnections is increasing the importance of material purity, formulation consistency and reliable chemical supply. Consequently, suppliers are competing not only through product portfolios but also through their ability to support customer qualification and localized…
Cross-Laminated Timber Market Set to Reach USD 6.2 Billion by 2033 | Cross-Lamin …
The global Cross-Laminated Timber Market is entering a new phase of industrial development as engineered wood moves beyond specialist timber construction into larger commercial, institutional and residential projects. Increasing attention to embodied carbon, prefabricated construction and domestic building-material supply chains is changing how developers evaluate structural materials. However, broader adoption depends on more than sustainability credentials. Manufacturers must demonstrate consistent structural performance, competitive delivered costs, reliable timber sourcing and compliance…
More Releases for NASH
The Growing Demand For NASH Treatment Amid Obesity Epidemic: A Key Catalyst Acce …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for non-alcoholic steatohepatitis (NASH) has seen a considerable expansion in the past few years. Its value is expected to rise from $4.5 billion in 2024 to $6.06 billion in 2025, marking…
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
